PRESS RELEASE
Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
111.2 EUR | +0.36% |
|
+1.83% | +3.06% |
07-11 | CAC40: maintains gains after reassuring US inflation figures | CF |
07-11 | CAC40: rise without volume, W-Street at its zenith but falls back | CF |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.06% | 9.96B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- IPN Stock
- News Ipsen
- IPSEN : announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET 1 patients with carcinoid syndrome met its primary endpoint